1. Academic Validation
  2. Bioadhesive drug-loaded microparticles prolong drug retention in the middle ear and ameliorate cisplatin-induced hearing loss

Bioadhesive drug-loaded microparticles prolong drug retention in the middle ear and ameliorate cisplatin-induced hearing loss

  • J Control Release. 2025 Jul 10:383:113728. doi: 10.1016/j.jconrel.2025.113728.
Zhi-Bin Zhou 1 Xue Bai 2 Zhi-Yong Zhou 3 Zi-Yue Lin 2 Bing Liao 2 Fei Gong 3 Mei-Qun Wang 2 Xu-Bo Chen 2 Yue-Hui Liu 4 Hong-Ping Chen 5 Kai Xu 6
Affiliations

Affiliations

  • 1 Department of Vascular Surgery, The Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • 2 Department of Otolaryngology, Head and Neck Surgery, The Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • 3 Center for Molecular Diagnosis and Precision Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • 4 Department of Otolaryngology, Head and Neck Surgery, The Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China. Electronic address: liuyuehuiclark@21cn.com.
  • 5 Department of Histology and Embryology, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China; The MOE Basic Research and lnnovation Center for the Targeted Therapeutics of Solid Tumors, School of Basic Medicine, China. Electronic address: jxchp2000@126.com.
  • 6 Department of Otolaryngology, Head and Neck Surgery, The Second Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China. Electronic address: ndefy21161@ncu.edu.cn.
Abstract

Hearing loss represents a common adverse effect following platinum-based chemotherapy regimens. The therapeutic management of inner ear diseases is significantly constrained by the blood-labyrinth barrier, which restricts the penetration of drug molecules into the endolymphatic, thereby limiting their therapeutic efficacy. Local drug delivery has emerged as a safe and effective method for the treatment of inner ear diseases. Nevertheless, the suboptimal retention duration of therapeutic agents within the middle ear substantially compromises drug delivery efficiency. To overcome this limitation, we designed and synthesized a methacrylate-gelatin microsphere (GH) conjugate polydopamine (PDA) layer (GH@PDA) with excellent adhesion ability. This engineered platform demonstrates rapid loading kinetics for bioactive molecules, enabling precise localized delivery of therapeutic payloads. Based on our findings that calcium overload and ROS accumulation are important mechanisms for cisplatin-induced hearing loss, we functionalized GH@PDA with both the nitric oxide (NO) precursor L-arginine and calmodulin-dependent kinase II inhibitor KN93 to construct the multifunctional composite GH@PDA@LK. In vivo imaging analyses revealed that the GH@PDA can prolong the retention of the middle ear and significantly increase the drug uptake concentration of the inner ear. Notably, intratympanic administration of GH@PDA@LK conferred robust protection against cisplatin-induced auditory threshold shifts and reduced outer hair cell loss in rat models. These findings collectively demonstrate that injectable GH@PDA microspheres constitute a clinically translatable platform for inner ear drug delivery. More importantly, our work establishes a novel mechanistically grounded therapeutic paradigm for preventing chemotherapy-induced ototoxicity through dual-pathway modulation of calcium signaling and oxidative stress.

Keywords

Calcium overload; Hearing loss; Local drug delivery; Microgel; Reactive oxygen species.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15465
    99.42%, CaMK II 抑制剂‎